LLY ▼ -0.5% - Eli Lilly and Company $LLY - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity 09-OCT-2026 06:45 AM ET